SEC For	m 4																	
	FORM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					iled pu	NT OF CHANGES IN BENEFICIAL OWNE ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								CMB Number: Estimated average burden hours per response:			3235-0287 n 0.5	
1. Name and Address of Reporting Person* Farah Sammy J.					2. Issuer Name and Ticker or Trading Symbol <u>Turnstone Biologics Corp.</u> [TSBX]								ck all applica Director	able)	10% Owner			
(Last) C/O TUI	C/O TURNSTONE BIOLOGICS CORP.					3. Date of Earliest Transaction (Month/Day/Year) 10/16/2023								X Officer (give title Other (specify below) below) President & CEO				
9310 ATHENA CIRCLE, SUITE 300 (Street) LA JOLLA CA 92037				- 4.	Line) X Form file									vint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting				
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/II)				sactio	ction 2A. Deemed Execution Da		ed Date	3. Transacti Code (Ins			or	5. Amoun	For ly (D)			7. Nature of Indirect Beneficial Ownership		
							ay/rea	Code V	Amou	nt (A (D	or Pr	Price Owned Report Transac (Instr. 3		d tion(s)		su. 4j	(Instr. 4)	
									uired, Dis s, options	•	,			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\	ate, 1	4. Transactior Code (Instr. 8)				6. Date Exerc Expiration D (Month/Day/	of Secu Underly Derivat	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiratio Date	n Title	Amor or Numl of Sh	ber		(Instr. 4)	.011(5)		
Employee Stock Option (Right to Buy)	\$2.61	10/16/2023			A		155,321		(1)	10/15/203	3 Commo Stock	ⁿ 155,	,321	\$0.00	155,3	21	D	

Explanation of Responses:

1. One fourth (1/4th) of the shares subject to the option award shall vest on October 12, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

<u>/s/ P. Joseph Campisi, Jr.,</u>	
Attorney-in-Fact	

Date

10/17/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.